Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer

Alexa R. Meyer, Gregory A. Joice, Mohamad E Allaf, Steven Rowe, Michael Gorin

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: To explore the current state of using prostate-specific membrane antigen (PSMA)-targeted PET imaging to aid in the diagnosis of clinically significant prostate cancer. RECENT FINDINGS: Prostate-specific antigen screening remains controversial, as it is associated with the underdetection of clinically significant prostate cancer as well as the overdetection and subsequent overtreatment of clinically insignificant disease. A diagnostic test that can accurately assess the presence of clinically significant prostate cancer and avoid detection of low-risk tumors is needed. Multiparametric magnetic resonance imaging (mpMRI) can aid in the detection of clinically significant prostate cancer and can be used with fusion-based biopsy platforms to target biopsies to specific lesions. However, there are several limitations of mpMRI including a modest negative predictive value for high-grade cancer. PSMA-targeted PET imaging has shown promise as a noninvasive test to aid in the detection of clinically significant prostate cancer while providing anatomical information to guide targeted biopsies. PSMA-targeted PET in combination with mpMRI offers a higher degree of diagnostic accuracy for imaging localized prostate cancer than either modality alone. SUMMARY: PSMA-targeted PET imaging can aid in the identification of men with clinically significant prostate cancer. Further research is needed to determine the full potential of PSMA-targeted imaging in both the detection and treatment of localized prostate cancer.

Original languageEnglish (US)
Pages (from-to)493-498
Number of pages6
JournalCurrent opinion in urology
Volume28
Issue number6
DOIs
StatePublished - Nov 1 2018

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer'. Together they form a unique fingerprint.

  • Cite this